Aligos Therapeutics Initiates Dosing with its Small Interfering RNA (siRNA) Drug Candidate, ALG-125755, in Subjects with Chronic Hepatitis B (CHB)

Saved in:
Bibliographic Details
Published inNews Bites US - NASDAQ
Format Newsletter
LanguageEnglish
Published Melbourne News Bites Pty Ltd 15.12.2022
Subjects
Drug dosages
Hepatitis B
Liver diseases
Present value
United States > US
Online AccessGet full text

Cover

More Information
Description not available.